Related Experiment Video
Updated: Jul 18, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
New ocular therapeutics: a view from the patenting perspective
1HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Wien, Austria. h.mucke@hmpharmacon.com
Idrugs : the Investigational Drugs Journal
|December 26, 2006
Summary
This review highlights recent therapeutic developments for ocular diseases, focusing on pharmaceutical industry intentions revealed through patent filings. It covers advancements in drug delivery, dry eye, infections, glaucoma, and age-related macular degeneration, including RNA interference applications.
Area of Science:
- Ophthalmology
- Pharmaceutical Science
- Biotechnology
Background:
- Patent literature offers insights into the pharmaceutical industry's drug development pipeline for ocular diseases.
- This review focuses on patents published between November 2005 and October 2006, a period of significant innovation.
- Understanding patent trends is crucial for anticipating future therapeutic interventions in eye care.
Purpose of the Study:
- To provide an overview of emerging therapeutic strategies for ocular diseases based on recent patent filings.
- To identify key areas of pharmaceutical industry focus, including drug delivery and specific eye conditions.
- To highlight the potential of novel technologies like RNA interference in ophthalmology.
Main Methods:
- Systematic review of patent applications and granted patents related to ocular therapeutics published from November 2005 to October 2006.
- Categorization of patents based on therapeutic area (e.g., dry eye, glaucoma, age-related macular degeneration) and technology (e.g., drug delivery, RNA interference).
- Analysis of patent content to identify novel compounds, formulations, and treatment modalities.
Main Results:
- Identified numerous patents detailing innovative drug delivery systems for enhanced ocular penetration and sustained release.
- Documented advancements in treatments for dry eye syndrome, ocular infections, and lesions, with a focus on novel active ingredients.
- Observed significant patent activity in glaucoma and age-related macular degeneration, including neuroprotective agents and anti-angiogenic therapies.
- Highlighted the growing interest in RNA interference (RNAi) as a therapeutic modality for various ocular conditions.
Conclusions:
- The patent landscape reveals a strong industry commitment to developing novel treatments for a range of ocular diseases.
- Emerging drug delivery technologies and targeted therapies, including RNAi, show considerable promise for future ophthalmic drug development.
- Continued monitoring of patent filings is essential for tracking innovation and anticipating the next generation of ocular therapeutics.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...